Pharmacokinetics of the phage endolysin-based candidate drug SAL200 in monkeys and its appropriate intravenous dosing period

Clinical and Experimental Pharmacology and Physiology

Volumn 43, Issue 10, 2016, Pages 1013-1016

  Jun, Soo Youn ^a   Jung, Gi Mo ^a   Yoon, Seong Jun ^a   Youm, So Young ^b   Han, Hyoung Yun ^b   Lee, Jong Hwa ^b   Kang, Sang Hyeon ^a  

^a INtRON Biotechnology Inc   (South Korea)

^b Korea Institute of Toxicology   (South Korea)

Author keywords

antibiotic resistant; intravenous administration; monkey; phage endolysin; staphylococci

Indexed keywords

ANTIBIOTIC AGENT; SAL 200; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG EXPOSURE; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; ELIMINATION HALF-LIFE; EXPERIMENTAL MONKEY; FEMALE; LETTER; MALE; MAXIMUM PLASMA CONCENTRATION; MEAN RESIDENCE TIME; MULTIPLE DRUG DOSE; NONHUMAN; PLASMA CONCENTRATION-TIME CURVE; SEX DIFFERENCE; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION;

EID: 84985019767     PISSN: 03051870     EISSN: 14401681     Source Type: Journal    
DOI: 10.1111/1440-1681.12613     Document Type: Letter

References (5)

1. Young I, Wang I, Roof WD. Phages will out: strategies of host cell lysis. Trends Microbiol. 2000;8:120–128.
2. Loessner MJ. Bacteriophage endolysins: current state of research and applications. Curr Opin Microbiol. 2005;8:480–487.
3. Jun SY, Jung GM, Son JS, Yoon SJ, Choi YJ, Kang SH. Comparison of the antibacterial properties of phage endolysins SAL-1 and LysK. Antimicrob Agents Chemother. 2011;55:1764–1767.
4. Jun SY, Jung GM, Yoon SJ, et al. Antibacterial properties of a pre-formulated recombinant phage endolysin, SAL-1. Int J Antimicrob Agents. 2013;41:156–161.
5. Jun SY, Jung GM, Yoon SJ, et al. Preclinical safety evaluation of intravenously administered SAL200 containing the recombinant phage endolysin SAL-1 as a pharmaceutical ingredient. Antimicrob Agents Chemother. 2014;58:2084–2088.